About us Pricing ContactSubscribe

articleTop 1% cited

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

The Lancet Oncology · 2016 · Vol. 17(4) · pp. 425–439

Massimo Cristofanilli✉(Robert H. Lurie Comprehensive Cancer Center of Northwestern University)Nicholas C. Turner(Royal Marsden Hospital)Igor Bondarenko(Dnipro State Medical University)Jungsil Ro(National Cancer Center)Seock‐Ah Im(Seoul National University Hospital)Norikazu Masuda(Osaka National Hospital)Marco Colleoni(European Institute of Oncology)Angela DeMichele(University of Pennsylvania)Sherene Loi(Peter MacCallum Cancer Centre)Sunil Verma(University of Calgary)Hiroji Iwata(Aichi Cancer Center)Nadia Harbeck(Ludwig-Maximilians-Universität München)Ke Zhang(Pfizer (United States))Kathy Puyana Theall(Pfizer (United States))Yuqiu Jiang(Pfizer (United States))Cynthia Huang Bartlett(Pfizer (United States))María Koehler(Pfizer (United States))Dennis J. Slamon(University of California, Los Angeles)

View via DOI Publisher page

Advanced Breast Cancer Therapies HER2/EGFR in Cancer Research Cancer Treatment and PharmacologyFulvestrantPalbociclibMetastatic breast cancerMedicinePlaceboInternal medicineOncologyGynecologyCancerBreast cancer

MeSH terms

FulvestrantAdultAgedBreast NeoplasmsDouble-Blind MethodEstradiolFemaleHumansMiddle AgedMutationNeoplasm MetastasisNeoplasm Recurrence, LocalPiperazinesPyridinesTreatment Outcome

Funding

U.S. Department of Defense
Eli Lilly and Company
Pfizer
AstraZeneca
GlaxoSmithKline
Novartis
Daiichi-Sankyo
University of California, Los Angeles

Citations

1,795

FWCI

150.16

field-weighted impact

References

32

Percentile

100%

vs. same field & year

Citations per year

Cited by

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences

Drugs · 2020 · 404 citations

4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

Annals of Oncology · 2018 · 1,168 citations

Recent Advances in the Treatment of Breast Cancer

Frontiers in Oncology · 2018 · 396 citations

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

Annals of Oncology · 2021 · 1,287 citations

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Annals of Oncology · 2016 · 2,058 citations

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

Annals of Oncology · 2020 · 1,319 citations

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

European Heart Journal · 2022 · 2,509 citations

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Annals of Oncology · 2018 · 845 citations

References

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

The Lancet Oncology · 2014 · 1,891 citations

Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.